• Second heterologous doses, Magrini: "Very high security"

  • Vaccini, Figliuolo: "Revision of the plan? Balanced doses in 11 Regions"

  • De Luca bans Astrazeneca and Johnson & Johnson under 60 and gives the green light to the vaccine mix

  • Palù: "Aifa recommendation is strong, State imposes itself on Regions autonomy"

  • Fedriga: "On AstraZeneca there was confusion of the regulatory bodies"

  • Vaccine: Aifa green light for a mix of vaccines for under 60s

Share

June 16, 2021On the second heterologous vaccine doses "we must be more than calm". DG Aifa, Nicola Magrini, told Rainews24. "In the decisions taken in this phase of the pandemic, less heavy than a few weeks ago, the choice was made - he explained - to avoid that in this phase young populations are potentially offered vaccines that have a very remote risk of a serious event, and therefore safety has been privileged to guarantee maximum safe vaccines for all ". It is a "choice also shared by several countries, so I believe that trust and maximum peace of mind is the message to be given".



Clinical studies, high safety

At the basis of the heterologous vaccination "there are clinical studies that were carried out with the utmost ethical rigor, but they were not particularly problematic studies. The question was whether there would be more undesirable effects and to what extent, and are mostly mild or moderate effects. , and therefore the safety as regards the administration is very high ". This was underlined to Rainews24 by the general director of the Italian armory agency (Aifa), Nicola Magrini. Even with regard to "long-term safety, or rather whether the vaccine mix is ​​problematic - found Magrini - this is excluded in light of the available data". Therefore, "having preferred this 'transfer' as a matter of utmost cautionon the second dose it was also a mixed principle of fairness to guarantee everyone the best vaccine free of these very rare side effects for which, when the pandemic was very serious - he concluded - it was instead decided, on the population at greatest risk, to offer a highly effective and globally safe vaccine ".





At this moment we need collaboration and trust

"Emotion is the result of unprecedented media participation, understandable, because the mass vaccination we are witnessing is an event that has never been seen before. But I think the word to use in this collaboration and trust, and a European and global vision, "Aifa general director Nicola Magrini told Rainews24, noting that" sharing the choices day by day with a very high media attention, to sometimes even with some protagonism of someone, it can spark discussions ". 



J&J further space for less frequent reactions

With respect to whether the AstraZeneca and J&J vaccines have the same positioning, "a further space has been left for J&J regarding the fact that side effects seem less frequent, much less, and therefore in the accumulation of data in the world it will be seen if this vaccine that is simpler in single doses can be somehow recovered for special populations in total safety ", said Magrini.